Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes
Mantle Cell Lymphoma
Explore 162 assets in Mantle Cell Lymphoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02153580CT.gov Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02051257CT.gov Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P1 | CC · 43 |
| B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma | — | P1 | CC · 43 |
| B-Cell Prolymphocytic Leukemia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-cd19car-cd28-cd3zeta-egfrt-expressing-tnmem-enriched-t-lymphocytes-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →